Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab + Chemotherapy +/- Tislelizumab in HER2+ Gastroesophageal Adenocarcinoma
NCT05152147Phase 3Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Dec 2021
- Primary completion
- Jul 2026
- Countries
- 33
01
Overview
A Phase 3 trial of zanidatamab in gastroesophageal adenocarcinoma, sponsored by Jazz Pharmaceuticals plc. Started Dec 2021; status: active, not recruiting.
02
Drugs
zanidatamab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT05152147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152147.